SEC For	m 4																	
FORM 4 UNITED STAT				TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section obligat	this box if no lo 1 16. Form 4 or ions may contir tion 1(b).		d purs	JT OF CHANGES IN BENEFICIAL OWNER									Estimated average burden			235-0287 0.5		
1. Name and Address of Reporting Person [*] Sebelius Kathleen					2. Issuer Name and Ticker or Trading Symbol Humacyte, Inc. [HUMA]									Officer (give title Other (n(s) to Issu 10% Ow Other (sp	ner
(Last) (First) (Middle) 2525 EAST NORTH CAROLINA HIGHWAY 54					3. Date of Earliest Transaction (Month/Day/Year) 08/26/2021									below) below)				
(Street) DURHAM NC 27713 (City) (State) (Zip)					Line									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(- 5)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution			Code (Ins	Transaction Disposed Of (D Code (Instr. 5)			s Acquired (A) or f (D) (Instr. 3, 4 and		s ally ollowing	6. Own Form: I (D) or I (I) (Inst	Direct o Indirect B tr. 4) C	7. Nature of Indirect Beneficial Ownership
									Code V	Amou	Int	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			nstr. 4)
		-	Fable II - D (e						uired, Dis , options,					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/ ^N) C	ransa ode (l		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y [(10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisable	Expiratio Date		Title	Amount or Number of Shares					
Stock Options (right to buy)	\$2.56	08/26/2021			Α		39,389		(1)	09/01/20	25	Common Stock	39,389	(2)	39,389		D	
Stock Options (right to buy)	\$6.54	08/26/2021			A		17,068		(1)	04/12/20	28	Common Stock	17,068	(2)	17,068		D	

Explanation of Responses:

1. Options are fully vested and exercisable.

2. On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.

/s/ Kathleen Sebelius by Dale 08/27/2021 A. Sander as Attorney-in-Fact Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.